United States Patent 9,044,480: Claim Scope, Exclusivity, and HCV Patent Landscape

U.S. Patent No. 9,044,480 protects treatment methods using ritonavir-boosted Compound I, identified in the patent disclosure as the HCV NS3/4A protease inhibitor ABT-450, now known as paritaprevir. The patent is directed to virologically difficult patient populations rather than treatment of HCV generally. Its principal limitations are the specified ABT-450 and ritonavir dose thresholds, patient genotype or resistance status, prior protease-inhibitor failure, and optional combination therapy.

The patent was assigned to AbbVie-related entities and issued on June 2, 2015. Its effective patent term is generally expected to extend to approximately July 2029, subject to any patent-term adjustment or other term calculation reflected in the official USPTO record. The patent does not independently protect ritonavir, paritaprevir as a chemical entity, or every paritaprevir-containing HCV regimen.

What drug does Compound I represent in U.S. Patent 9,044,480?

Compound I is ABT-450, also called paritaprevir. Paritaprevir is an HCV NS3/4A protease inhibitor whose exposure is increased by coadministration with ritonavir. The marketed combination was incorporated into AbbVie's Viekira Pak and Viekira XR products, which also contained ombitasvir and dasabuvir. Paritaprevir and ritonavir were also used with ombitasvir in Technivie for certain genotype 4 infections. [1][2]

The commercial pharmacologic combination was:

Component	Role
Paritaprevir, formerly ABT-450	HCV NS3/4A protease inhibitor
Ritonavir	Pharmacokinetic enhancer through CYP3A inhibition
Ombitasvir	HCV NS5A inhibitor
Dasabuvir	Non-nucleoside HCV NS5B polymerase inhibitor

The patent claims do not require ombitasvir or dasabuvir in independent form. Claims 3, 6, and 9 instead permit an additional anti-HCV agent from specified mechanistic classes.

What patient populations does Patent 9,044,480 cover?

The claims target three patient categories.

HCV patients with R155 or D168 resistance mutations

Claims 1 through 3 cover treatment of an HCV patient harboring an R155 or D168 resistant mutant. These are mutations in the HCV NS3 protease region associated with reduced susceptibility to certain protease inhibitors.

The claim requires:

At least 150 mg per day of Compound I;
At least 50 mg per day of ritonavir; and
Treatment of a patient harboring an R155 or D168 resistant mutant.

Claim 2 narrows the regimen to:

200 mg per day of Compound I; and
100 mg per day of ritonavir.

Claim 3 adds optional combination therapy with another anti-HCV agent.

Treatment-experienced patients who failed another protease inhibitor

Claims 4 through 6 cover a patient who:

Has HCV;
Is treatment-experienced;
Previously received another protease inhibitor;
Failed that treatment because at least one resistant mutation emerged; and
Receives the specified Compound I and ritonavir regimen.

The prior treatment failure must be causally connected to emergence of a resistant mutation. A patient who merely failed therapy for nonvirologic reasons, such as intolerance or nonadherence, would not necessarily satisfy this limitation.

Patients with a non-CC IL28B genotype

Claims 7 through 9 cover patients with a non-CC IL28B rs12979860 genotype. The relevant genotypes are generally CT and TT. The claim requires the same minimum dosing thresholds and contains a dependent claim specifying 200 mg per day of Compound I with 100 mg per day of ritonavir.

The IL28B limitation is a host-genetic selection criterion. It distinguishes patients historically associated with a weaker response to interferon-based HCV treatment.

How do the claims differ from one another?

Claims	Patient-selection limitation	Minimum regimen	Narrower regimen	Combination therapy
1-3	R155 or D168 resistant mutant	150 mg Compound I plus 50 mg ritonavir daily	200 mg plus 100 mg daily	Claims 3
4-6	Prior protease-inhibitor failure caused by resistant mutation	150 mg plus 50 mg daily	200 mg plus 100 mg daily	Claims 6
7-9	Non-CC IL28B rs12979860 genotype	150 mg plus 50 mg daily	200 mg plus 100 mg daily	Claims 9

The independent claims are method-of-treatment claims. Each requires administration to a qualifying patient. The claims do not cover possession, manufacture, or sale of Compound I alone.

What dosage limitations does Patent 9,044,480 impose?

The independent claims use minimum daily dose limitations:

At least 150 mg per day of Compound I; and
At least 50 mg per day of ritonavir.

The dependent claims specify:

200 mg per day of Compound I; and
100 mg per day of ritonavir.

The phrase “at least” creates a broad quantitative limitation. A regimen above the stated threshold can fall within the literal dose language if the other claim elements are met. The analysis must account for whether the dose is administered as a total daily dose, how divided dosing is treated, and whether the product label or clinical records establish the amount administered.

The claims also cover pharmaceutically acceptable salts. A salt form of Compound I or ritonavir is not outside the claim solely because it is not the free-base form, provided it is the claimed active compound or salt.

What formulation patents are separate from Patent 9,044,480?

Patent 9,044,480 is not principally a formulation patent. It does not claim a tablet composition, excipient system, release profile, fixed-dose package, or manufacturing process in the claims provided.

The patent landscape for paritaprevir-based products includes separate categories:

Patent category	Typical protected subject matter	Relevance to Patent 9,044,480
Compound patents	Paritaprevir chemical structure and analogs	Separate chemical-entity protection
Salt and solid-form patents	Crystalline forms, salts, polymorphs	Potential product and manufacturing barriers
Combination patents	Paritaprevir with ritonavir, ombitasvir, or dasabuvir	May overlap commercially but not necessarily claim 9,044,480
Formulation patents	Tablets, dosage units, excipients, packaging	Usually separate from the treatment claims
Method-of-use patents	Genotype, resistance, prior-treatment, or dosing populations	Patent 9,044,480 falls in this category
Manufacturing patents	Synthetic routes and intermediates	Relevant to API suppliers and ANDA risk
Regulatory exclusivity	New-drug, orphan, or pediatric exclusivity	Separate from patent term

A generic or authorized-generic strategy can face separate risks from the active-ingredient patent estate, formulation patents, and method-of-use claims even if one patent is invalidated or expires.

What is the Orange Book status of paritaprevir and Viekira products?

The FDA approved Viekira Pak in December 2014 and Viekira XR in July 2016. Technivie was approved in July 2015. The products were approved for HCV treatment in combination with other agents and, in some cases, ribavirin. [1][2]

FDA Orange Book listings must be assessed by product and application number because a patent may be listed against one approved product but not another. The relevant listed-patent questions include:

Whether U.S. Patent 9,044,480 was submitted for Viekira Pak, Viekira XR, or another paritaprevir-containing product;
The patent-use code associated with the listing;
Whether the listing covers the approved method of use;
Whether the listing remains active in the current FDA database; and
Whether the relevant product has been discontinued while the application remains listed.

A method-of-use patent can be listed in the Orange Book if it claims an approved use of the drug. Listing does not establish validity or infringement. The FDA does not adjudicate those issues. [3]

When does U.S. Patent 9,044,480 lose exclusivity?

The patent issued on June 2, 2015. Public patent records associate the patent family with a July 2009 priority date and an expected expiration in approximately July 2029. The precise expiration date must be taken from the USPTO patent-term calculation because patent-term adjustment, terminal disclaimers, patent-term extension, and disclaimer records can affect the operative date. [4]

The patent is not a conventional New Chemical Entity patent. Its duration is therefore separate from any five-year NCE exclusivity period for paritaprevir. FDA regulatory exclusivity for Viekira products would have begun with product approval and would not normally extend to the expected 2029 patent expiration.

Because paritaprevir-based products have been commercially displaced by newer regimens, the practical commercial value of the remaining patent term is lower than the legal term suggests.

Which patents provide the broader paritaprevir patent estate?

The paritaprevir estate is broader than Patent 9,044,480. It historically included patent families directed to:

The paritaprevir chemical series;
Protease-inhibitor compounds and stereochemical forms;
Combination treatment with ritonavir;
Fixed-dose combinations with ombitasvir and dasabuvir;
Genotype-specific HCV treatment;
Resistance-associated substitutions;
Solid forms and pharmaceutical compositions; and
Synthetic intermediates and manufacturing processes.

Patent 9,044,480 is comparatively narrow because it requires a defined patient phenotype or treatment history. It is broader in one respect: it does not require a particular commercial product containing ombitasvir or dasabuvir. A regimen using another qualifying anti-HCV agent could satisfy the optional combination claims if all other limitations are met.

How strong are the claims under a patent-validity analysis?

The claims have several strength factors.

Features supporting enforceability

The claims contain measurable and clinically identifiable limitations:

Specific mutations, R155 or D168;
A defined prior protease-inhibitor failure pathway;
A defined IL28B genotype;
Stated daily doses; and
A particular active compound combined with ritonavir.

These limitations can make anticipation more difficult than for a broad claim covering all use of paritaprevir. The claims also focus on patient subgroups that were relevant to HCV resistance management.

Potential validity pressure points

The principal validity issues would likely involve:

Whether the claimed patient-selection strategy was obvious from preexisting resistance data;
Whether the prior art disclosed ritonavir-boosted ABT-450 at the claimed doses;
Whether the specification supports the full scope of “at least” dosing;
Whether the patent adequately demonstrates treatment of each claimed mutation or genotype;
Whether the R155 and D168 limitations are sufficiently defined in relation to genotype and assay methodology;
Whether the claim language creates written-description or enablement issues; and
Whether an earlier family member or published application disclosed the same regimen.

The optional combination-agent language in claims 3, 6, and 9 expands the treatment context but may create additional written-description and obviousness questions if the specification does not provide sufficient support across every listed agent class.

What Paragraph IV challenges could target this patent?

An ANDA applicant seeking approval for a product that references a paritaprevir-containing product could address Patent 9,044,480 through a Paragraph IV certification if the patent is listed and the applicant asserts that the patent is invalid, unenforceable, or not infringed. [5]

Possible noninfringement positions include:

The proposed product is not paritaprevir or Compound I;
The proposed label does not direct treatment of R155 or D168 mutants;
The label does not identify treatment-experienced patients who failed another protease inhibitor because of resistance;
The label does not select patients by IL28B genotype;
The regimen uses less than the claimed minimum doses;
The regimen uses a different dosing schedule that does not satisfy the daily-dose limitation; or
The product is not approved for the claimed method.

A label-sparing strategy is especially relevant because the patent claims depend on patient selection. A generic applicant may seek to omit the patented subgroup from its labeling while retaining approval for unpatented uses. That strategy depends on FDA labeling rules, the scope of the approved reference product, inducement principles, and the actual language of the proposed label.

What patent litigation and settlements affect Patent 9,044,480?

The material commercial litigation risk historically centered on AbbVie's HCV franchise, competing direct-acting antivirals, and generic or licensing disputes involving older HCV products. Patent 9,044,480 should not be treated as a standalone litigation asset without reviewing:

District court docket history;
Federal Circuit decisions;
Inter partes review records;
Patent-term and terminal-disclaimer records;
Orange Book listing history; and
Any license or settlement agreement governing paritaprevir products.

The claim set does not itself establish a settlement, license, covenant not to sue, or enforceability outcome. A settlement may limit practical enforcement without changing the face of the patent or its expiration date.

How does Patent 9,044,480 compare with modern HCV competition?

Paritaprevir-based therapy has been overtaken by pangenotypic fixed-dose combinations with shorter treatment courses and simpler dosing. The principal commercial competitors include:

Product	Main active agents	Commercial position
Viekira Pak	Ombitasvir, paritaprevir, ritonavir, dasabuvir	Earlier genotype-specific regimen; largely displaced
Viekira XR	Ombitasvir, paritaprevir, ritonavir, dasabuvir	Extended-release version of the same platform
Technivie	Ombitasvir, paritaprevir, ritonavir	Genotype 4 regimen, used with ribavirin in the original label
Harvoni	Ledipasvir and sofosbuvir	NS5A/NS5B combination
Epclusa	Velpatasvir and sofosbuvir	Broad pangenotypic coverage
Mavyret	Glecaprevir and pibrentasvir	Pangenotypic regimen with strong commercial displacement

The closest mechanistic competitor is a protease-inhibitor-containing regimen such as glecaprevir/pibrentasvir. That product does not use paritaprevir and does not ordinarily fall within the literal Compound I limitation of Patent 9,044,480.

What generic-entry risks exist for paritaprevir products?

Legal entry risk and commercial entry risk differ.

Legal risks include:

Remaining Orange Book-listed patents;
Product, formulation, and combination patents separate from this patent;
Paragraph IV litigation;
Induced-infringement exposure from label language;
Manufacturing patents covering paritaprevir intermediates; and
Regulatory requirements for a complex combination product.

Commercial risks include:

Limited demand for Viekira-era regimens;
Physician preference for pangenotypic therapies;
Product discontinuation or restricted availability;
Low expected return on a complex multi-ingredient ANDA; and
Potential difficulty obtaining or sourcing all active ingredients.

A generic launch could occur through an at-risk launch, a negotiated license, an authorized generic arrangement, or a later launch after patent expiry. The value of a 2029 launch would depend on whether a commercially viable reference product and market remain.

Does Patent 9,044,480 cover biosimilars?

No. Biosimilar law does not apply to paritaprevir or ritonavir because both are small-molecule drugs. A competing product would generally use the ANDA pathway for a qualifying small-molecule reference product, not the 351(k) biosimilar pathway. [6]

The relevant competitive threat is generic or abbreviated-application entry, not biosimilar substitution.

Key Takeaways

U.S. Patent 9,044,480 is a method-of-treatment patent for ritonavir-boosted ABT-450, or paritaprevir.
The claims focus on resistant HCV patients, prior protease-inhibitor failures caused by resistance, and non-CC IL28B genotypes.
The core dosing threshold is at least 150 mg per day of Compound I and at least 50 mg per day of ritonavir.
Dependent claims specify 200 mg per day of Compound I and 100 mg per day of ritonavir.
Optional combination therapy claims cover additional HCV polymerase, NS5A, cyclophilin, CD81, or IRES inhibitors.
The patent does not independently claim paritaprevir as a chemical compound, a formulation, or every paritaprevir-containing product.
The expected patent term runs approximately to July 2029, subject to the official USPTO term calculation.
Orange Book status must be assessed by product, application number, patent-use code, and current listing record.
The patent is legally narrower than a compound or formulation patent but may create label-based infringement risk for a product directed to the claimed patient populations.
Commercial value is constrained by the displacement of Viekira products by pangenotypic HCV regimens.

Frequently Asked Questions

What is the difference between claims 1 and 4 of Patent 9,044,480?

Claim 1 requires an R155 or D168 resistant mutant. Claim 4 instead requires prior failure of another protease inhibitor because at least one resistant mutation emerged. The two patient populations can overlap but are not identical.

Does a regimen containing 200 mg of paritaprevir and 100 mg of ritonavir automatically infringe?

No. The dose is only one element. The patient must also satisfy the relevant mutation, treatment-failure, or IL28B-genotype limitation, and the administered compound must correspond to Compound I or its qualifying salt.

Can a generic omit the resistant-patient indication from its label?

A generic applicant may consider a label-sparing approach, but the outcome depends on the scope of the reference label, FDA approval requirements, the proposed labeling, and inducement-of-infringement principles.

Are R155 and D168 mutations present in all HCV genotypes?

No. Resistance-associated substitutions are genotype- and subtype-dependent. The claim must be applied using the relevant HCV sequence position and assay conventions for the infected subtype.

Is ritonavir itself protected by Patent 9,044,480?

No. The patent uses ritonavir as part of the claimed treatment method. It does not create new exclusivity for ritonavir as an active pharmaceutical ingredient.

References

U.S. Food and Drug Administration. (2014). FDA approves Viekira Pak to treat hepatitis C.
U.S. Food and Drug Administration. (2015). FDA approves Technivie for treatment of hepatitis C genotype 4.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
United States Patent and Trademark Office. (2015). U.S. Patent No. 9,044,480, methods for treating hepatitis C virus infection.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions and Paragraph IV certifications.
U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biologic products.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No	9,044,480	⤷ Start Trial				TREATMENT OF HCV INFECTION USING PARITAPREVIR	⤷ Start Trial
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No	9,044,480	⤷ Start Trial				TREATMENT OF HCV INFECTION USING PARITAPREVIR	⤷ Start Trial
Abbvie	VIEKIRA PAK (COPACKAGED)	dasabuvir sodium; ombitasvir, paritaprevir, ritonavir	TABLET;ORAL	206619-001	Dec 19, 2014		DISCN	Yes	No	9,044,480	⤷ Start Trial				TREATMENT OF HCV INFECTION USING PARITAPREVIR	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 9,044,480

Which drugs does patent 9,044,480 protect, and when does it expire?

Summary for Patent: 9,044,480